Pharmaceutical preparations in the nature of recombinant human albuminous preparations for the treatment of hypovolemic shock, adult respiratory distress syndrome, major injury or surgery resulting in increased albumin loss or inadequate synthesis, acute nephrosis not responding to cyclophosphamide or steroid therapy, and acute liver failure or ascites where the therapeutic use is regulated by the individual circumstances; pharmaceutical preparations in the nature of recombinant human albuminous preparations as an adjunct in hemodialysis for patients undergoing long-term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of shock or hypertension; pharmaceutical preparations in the nature of recombinant human albuminous preparations for the treatment of cardiac disease in cardiopulmonary bypass procedures; pharmaceutical preparations in the nature of recombinant human albuminous preparations in conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia; pharmaceutical preparations in the nature of recombinant human albuminous preparations for use in the treatment of conditions in which there is severe hypoalbuminemia